首页 > 最新文献

Postgraduate medicine最新文献

英文 中文
The platelet-albumin-bilirubin score in predicting hepatic failure after TACE for non-small hepatocellular carcinoma. 血小板-白蛋白-胆红素评分预测非小肝细胞癌TACE术后肝衰竭
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-11-13 DOI: 10.1080/00325481.2025.2587342
Wenxiang Liang, Hankun Yuan, Jiajie Zhou, Sizong Chen, Heqian Huang, Liang Xu, Yufei Ma, Yuan Lu, Zongjiang Luo, Libai Lu, Jiasheng Ma, Zhenrong Zhao, Jianchu Wang

Objective: To evaluate the predictive value of the platelet-albumin-bilirubin (PALBI) score for hepatic failure after transarterial chemoembolization (TACE) in patients with non-small hepatocellular carcinoma (HCC) (tumor diameter > 5 cm).

Methods: A retrospective study included 577 non-small HCC patients who underwent TACE between January 2018 and December 2024. Patients were stratified by PALBI grade (Grade 1: ≤-2.53; Grade 2: > -2.53 to ≤-2.09; Grade 3: > -2.09). Hepatic failure was defined and graded (A-C) according to ISGLS criteria. The predictive efficacy of PALBI, ALBI, and Child-Pugh scores was compared using ROC curves.

Results: Hepatic failure occurred in 28.2% (163/577) of patients (Grade A: 22.0%; B: 4.6%; C: 1.5%). Hepatic failure incidence significantly increased with PALBI grade: 10.31% (Grade 1), 27.83% (Grade 2), and 78.95% (Grade 3) (p < 0.001). PALBI demonstrated superior predictive efficacy (AUC = 0.746) compared to ALBI (AUC = 0.702, p = 0.004) and Child-Pugh (AUC = 0.706, p = 0.075). Multivariate analysis identified ascites, AST, and total bilirubin as independent risk factors for hepatic failure (p < 0.05).

Conclusion: The PALBI score is an effective tool for predicting hepatic failure after TACE in non-small HCC patients. PALBI Grade 3 indicates high risk (78.95%), suggesting preoperative liver protection therapy before TACE. PALBI outperforms ALBI and Child-Pugh scores in risk stratification.

目的:探讨血小板-白蛋白-胆红素(PALBI)评分对非小肝细胞癌(HCC)患者经动脉化疗栓塞(TACE)后肝功能衰竭的预测价值。方法:一项回顾性研究包括577例在2018年1月至2024年12月期间接受TACE治疗的非小肝癌患者。患者按PALBI分级进行分层(1级:≤-2.53;2级:> -2.53至≤-2.09;3级:> -2.09)。根据ISGLS标准定义肝衰竭并分级(A-C)。采用ROC曲线比较PALBI、ALBI和Child-Pugh评分的预测效果。结果:28.2%(163/577)的患者发生肝功能衰竭(A级:22.0%,B级:4.6%,C级:1.5%)。肝功能衰竭发生率随PALBI分级显著增加:10.31%(1级)、27.83%(2级)和78.95%(3级)(p p = 0.004)和Child-Pugh (AUC = 0.706, p = 0.075)。多因素分析发现,腹水、AST和总胆红素是肝衰竭的独立危险因素(p)。结论:PALBI评分是预测非小肝癌患者TACE术后肝衰竭的有效工具。PALBI 3级提示高危(78.95%),建议在TACE前进行术前肝保护治疗。PALBI在风险分层方面优于ALBI和Child-Pugh评分。
{"title":"The platelet-albumin-bilirubin score in predicting hepatic failure after TACE for non-small hepatocellular carcinoma.","authors":"Wenxiang Liang, Hankun Yuan, Jiajie Zhou, Sizong Chen, Heqian Huang, Liang Xu, Yufei Ma, Yuan Lu, Zongjiang Luo, Libai Lu, Jiasheng Ma, Zhenrong Zhao, Jianchu Wang","doi":"10.1080/00325481.2025.2587342","DOIUrl":"10.1080/00325481.2025.2587342","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the predictive value of the platelet-albumin-bilirubin (PALBI) score for hepatic failure after transarterial chemoembolization (TACE) in patients with non-small hepatocellular carcinoma (HCC) (tumor diameter > 5 cm).</p><p><strong>Methods: </strong>A retrospective study included 577 non-small HCC patients who underwent TACE between January 2018 and December 2024. Patients were stratified by PALBI grade (Grade 1: ≤-2.53; Grade 2: > -2.53 to ≤-2.09; Grade 3: > -2.09). Hepatic failure was defined and graded (A-C) according to ISGLS criteria. The predictive efficacy of PALBI, ALBI, and Child-Pugh scores was compared using ROC curves.</p><p><strong>Results: </strong>Hepatic failure occurred in 28.2% (163/577) of patients (Grade A: 22.0%; B: 4.6%; C: 1.5%). Hepatic failure incidence significantly increased with PALBI grade: 10.31% (Grade 1), 27.83% (Grade 2), and 78.95% (Grade 3) (<i>p</i> < 0.001). PALBI demonstrated superior predictive efficacy (AUC = 0.746) compared to ALBI (AUC = 0.702, <i>p</i> = 0.004) and Child-Pugh (AUC = 0.706, <i>p</i> = 0.075). Multivariate analysis identified ascites, AST, and total bilirubin as independent risk factors for hepatic failure (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The PALBI score is an effective tool for predicting hepatic failure after TACE in non-small HCC patients. PALBI Grade 3 indicates high risk (78.95%), suggesting preoperative liver protection therapy before TACE. PALBI outperforms ALBI and Child-Pugh scores in risk stratification.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"799-806"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The predictive value of D-dimer and neutrophil-to-lymphocyte ratio for the severity of severe pneumonia in children. d -二聚体和中性粒细胞与淋巴细胞比值对儿童重症肺炎严重程度的预测价值。
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-11-18 DOI: 10.1080/00325481.2025.2587365
Yuan Wang, Mengjin Wang, Jingwei Sun

Objective: Severe pneumonia is typically characterized by severe pulmonary inflammatory responses. This study evaluated the predictive value of D-dimer (DD) and neutrophil-to-lymphocyte ratio (NLR) for disease severity in children with severe pneumonia.

Methods: Children with severe pneumonia (280 cases) were enrolled and divided into the critical and non-critical groups based on the pediatric critical illness score (PCIS). Clinical data were collected at patients' initial admission. Correlations of DD and NLR with the PCIS, their predictive value and the independent predictors for disease severity in children with severe pneumonia were assessed by Spearman test, receiver operating characteristic curve and multivariate logistic regression. Outcomes were determined as per the 28-day disease progression.

Results: The critical group showed higher DD and NLR than the non-critical group. DD and NLR negatively correlated with the PCIS. Children in the higher DD quartile group showed higher systolic blood pressure (SBP), NLR and procalcitonin, and lower platelet and PCIS. Children in the higher NLR quartile group had higher SBP, DD and procalcitonin, and platelet and lower PCIS. Areas under the curve to predict severe pneumonia severity were 0.805, 0.883 and 0.918 for DD, NLR and their combination, suggesting superior diagnostic value of their combination for disease severity. The critical group (59.05%) had higher 28-day poor outcomes of pneumonia than the non-critical group (18.29%). DD and NLR were independent risk factors for the disease severity in severe pneumonia children.

Conclusion: Elevated DD and NLR have certain predictive value for disease severity and poor prognosis in severe pneumonia children.

目的:重症肺炎的典型特征是严重的肺部炎症反应。本研究评估了d -二聚体(DD)和中性粒细胞与淋巴细胞比值(NLR)对重症肺炎患儿疾病严重程度的预测价值。方法:选取280例重症肺炎患儿,根据儿童危重疾病评分(PCIS)分为危重组和非危重组。在患者初次入院时收集临床资料。采用Spearman检验、受试者工作特征曲线及多因素logistic回归评估DD、NLR与PCIS的相关性、PCIS的预测值及重症肺炎患儿疾病严重程度的独立预测因子。结果根据28天的疾病进展来确定。结果:危重组的DD和NLR均高于非危重组。DD和NLR与PCIS呈负相关。高DD四分位数组儿童收缩压(SBP)、NLR和降钙素原较高,血小板和PCIS较低。NLR较高的四分位数组患儿收缩压、DD、降钙素原较高,血小板和PCIS较低。DD、NLR及其联合预测重症肺炎严重程度的曲线下面积分别为0.805、0.883、0.918,提示其联合对疾病严重程度有较好的诊断价值。危重组28天肺炎不良结局(59.05%)高于非危重组(18.29%)。DD和NLR是影响重症肺炎患儿病情严重程度的独立危险因素。结论:DD、NLR升高对重症肺炎患儿病情严重程度及预后不良有一定的预测价值。
{"title":"The predictive value of D-dimer and neutrophil-to-lymphocyte ratio for the severity of severe pneumonia in children.","authors":"Yuan Wang, Mengjin Wang, Jingwei Sun","doi":"10.1080/00325481.2025.2587365","DOIUrl":"10.1080/00325481.2025.2587365","url":null,"abstract":"<p><strong>Objective: </strong>Severe pneumonia is typically characterized by severe pulmonary inflammatory responses. This study evaluated the predictive value of D-dimer (DD) and neutrophil-to-lymphocyte ratio (NLR) for disease severity in children with severe pneumonia.</p><p><strong>Methods: </strong>Children with severe pneumonia (280 cases) were enrolled and divided into the critical and non-critical groups based on the pediatric critical illness score (PCIS). Clinical data were collected at patients' initial admission. Correlations of DD and NLR with the PCIS, their predictive value and the independent predictors for disease severity in children with severe pneumonia were assessed by Spearman test, receiver operating characteristic curve and multivariate logistic regression. Outcomes were determined as per the 28-day disease progression.</p><p><strong>Results: </strong>The critical group showed higher DD and NLR than the non-critical group. DD and NLR negatively correlated with the PCIS. Children in the higher DD quartile group showed higher systolic blood pressure (SBP), NLR and procalcitonin, and lower platelet and PCIS. Children in the higher NLR quartile group had higher SBP, DD and procalcitonin, and platelet and lower PCIS. Areas under the curve to predict severe pneumonia severity were 0.805, 0.883 and 0.918 for DD, NLR and their combination, suggesting superior diagnostic value of their combination for disease severity. The critical group (59.05%) had higher 28-day poor outcomes of pneumonia than the non-critical group (18.29%). DD and NLR were independent risk factors for the disease severity in severe pneumonia children.</p><p><strong>Conclusion: </strong>Elevated DD and NLR have certain predictive value for disease severity and poor prognosis in severe pneumonia children.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"790-798"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145544737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of clinical findings in predicting the development of serotonin syndrome: can the Hunter's criteria be used in children? 预测血清素综合征发展的临床表现评价:亨特标准可用于儿童吗?
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-11-21 DOI: 10.1080/00325481.2025.2592356
Ahmet Serkan Özcan, Raziye Merve Yaradilmiş, Bilge Akkaya, Fatma Şule Erdem, Orkun Aydin, Betül Öztürk, Ali Güngör, Nilden Tuygun

Objectives: Serotonin syndrome (SS) is a life-threatening emergency that develops as a result of increased serotonin amount or activity in the synaptic cleft. The present study aimed to determine the clinical findings in serotonergic drug intoxications in children that may alert clinicians about the development of SS.

Methods: The patients aged between 1 to 18 years, who were admitted to the pediatric emergency department (PED) because of drug intoxications between September 2022 and August 2024, were analyzed retrospectively. Patients with a history of taking one or more serotonergic drugs were included in the study. Patients were divided into two groups: SS and without SS. The sensitivity, specificity, negative and positive predictive value (PPV) of the Hunter's criteria and SS-related symptoms were evaluated.

Results: A total of 162 patients were included in the study. SS developed in 25 (15.4%) of the patients. SS developed in 23 (21.1%) of 109 patients receiving SSRI group drugs, while SS developed in two (4.8%) of 42 patients receiving non-SSRI group drugs (p = 0.015). Nineteen (76%) of the patients diagnosed with serotonin syndrome were also diagnosed with SS according to Hunter's criteria, and the sensitivity and specificity of Hunter's criteria in the diagnosis of SS in pediatric patients were 76% and 100%, respectively. The specificity and PPV were 100% for spontaneous clonus, inducible clonus, ocular clonus, hyperreflexia, and hyperthermia in the diagnosis of serotonin syndrome. The symptoms with the highest sensitivity were mydriasis (76%) and tremor (64%). All patients with serotonin syndrome were treated with cyproheptadine, and clinical findings improved.

Conclusion: SS developed in 15.4% of patients with serotonergic drug intoxication, and the sensitivity of Hunter's criteria for the diagnosis of SS was 76%. The combined use of Hunter's criteria and clinician decision in the diagnosis of childhood SS may be more useful.

目的:血清素综合征(SS)是一种危及生命的紧急情况,是由于突触间隙中血清素数量或活性增加而发展起来的。方法:回顾性分析2022年9月至2024年8月期间因5 -羟色胺能药物中毒在儿科急诊科(PED)就诊的1 ~ 18岁儿童患者的临床资料。有服用一种或多种血清素能药物史的患者被纳入研究。将患者分为SS组和非SS组,评估Hunter’s标准的敏感性、特异性、阴性和阳性预测值(PPV)及SS相关症状。结果:共纳入162例患者。25例(15.4%)患者发生SS。109例接受SSRI组药物的患者中有23例(21.1%)发生SS, 42例接受非SSRI组药物的患者中有2例(4.8%)发生SS (p = 0.015)。在诊断为5 -羟色胺综合征的患者中,有19例(76%)同时根据Hunter’s标准诊断为SS, Hunter’s标准诊断儿科患者SS的敏感性为76%,特异性为100%。自发性结膜炎、诱导性结膜炎、眼结膜炎、反射性亢进、高热诊断血清素综合征的特异性和PPV均为100%。敏感性最高的症状为滴虫(76%)和震颤(64%)。所有5 -羟色胺综合征患者均应用赛庚啶治疗,临床表现均有改善。结论:血清素能药物中毒患者发生SS的比例为15.4%,亨特标准诊断SS的敏感性为76%。在儿童期SS的诊断中,联合使用亨特标准和临床医生的决定可能更有用。
{"title":"Evaluation of clinical findings in predicting the development of serotonin syndrome: can the Hunter's criteria be used in children?","authors":"Ahmet Serkan Özcan, Raziye Merve Yaradilmiş, Bilge Akkaya, Fatma Şule Erdem, Orkun Aydin, Betül Öztürk, Ali Güngör, Nilden Tuygun","doi":"10.1080/00325481.2025.2592356","DOIUrl":"10.1080/00325481.2025.2592356","url":null,"abstract":"<p><strong>Objectives: </strong>Serotonin syndrome (SS) is a life-threatening emergency that develops as a result of increased serotonin amount or activity in the synaptic cleft. The present study aimed to determine the clinical findings in serotonergic drug intoxications in children that may alert clinicians about the development of SS.</p><p><strong>Methods: </strong>The patients aged between 1 to 18 years, who were admitted to the pediatric emergency department (PED) because of drug intoxications between September 2022 and August 2024, were analyzed retrospectively. Patients with a history of taking one or more serotonergic drugs were included in the study. Patients were divided into two groups: SS and without SS. The sensitivity, specificity, negative and positive predictive value (PPV) of the Hunter's criteria and SS-related symptoms were evaluated.</p><p><strong>Results: </strong>A total of 162 patients were included in the study. SS developed in 25 (15.4%) of the patients. SS developed in 23 (21.1%) of 109 patients receiving SSRI group drugs, while SS developed in two (4.8%) of 42 patients receiving non-SSRI group drugs (<i>p</i> = 0.015). Nineteen (76%) of the patients diagnosed with serotonin syndrome were also diagnosed with SS according to Hunter's criteria, and the sensitivity and specificity of Hunter's criteria in the diagnosis of SS in pediatric patients were 76% and 100%, respectively. The specificity and PPV were 100% for spontaneous clonus, inducible clonus, ocular clonus, hyperreflexia, and hyperthermia in the diagnosis of serotonin syndrome. The symptoms with the highest sensitivity were mydriasis (76%) and tremor (64%). All patients with serotonin syndrome were treated with cyproheptadine, and clinical findings improved.</p><p><strong>Conclusion: </strong>SS developed in 15.4% of patients with serotonergic drug intoxication, and the sensitivity of Hunter's criteria for the diagnosis of SS was 76%. The combined use of Hunter's criteria and clinician decision in the diagnosis of childhood SS may be more useful.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"807-813"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guaifenesin and dextromethorphan for management of cough and mucus-related cold symptoms in adults: a narrative literature review. 愈创甘油醚和右美沙芬治疗成人咳嗽和黏液相关感冒症状:叙述性文献综述
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-12-21 DOI: 10.1080/00325481.2025.2603034
M Thomas Bateman, Stephen Brunton, Wendy L Wright

Objectives: For many decades, guaifenesin and dextromethorphan have been two of the most well-established and commonly used nonprescription medications to manage cough and cold symptoms. A single source that summarizes the clinical data supporting the use of guaifenesin and dextromethorphan as self-care treatment options in cough and cold could assist healthcare professionals (HCPs) in making informed recommendations to patients. The objective of this narrative review is to discuss the benefits of guaifenesin and dextromethorphan for the management of cough and mucus-related cold symptoms in adults by examining published data on the effectiveness and safety of the products containing these ingredients.

Methods: Literature searches were performed on PubMed, Embase, and MEDLINE to identify randomized, controlled studies comparing guaifenesin or dextromethorphan treatment with placebo control in adults with cough and cold (mucus) symptoms. Of 36 guaifenesin and 53 dextromethorphan clinical studies initially identified by the literature search, 13 guaifenesin and 19 dextromethorphan publications met the predefined inclusion criteria. Additional studies were identified during manuscript development by reviewing the citations of included articles, for a total of 17 guaifenesin and 21 dextromethorphan publications.

Results: Data from studies of guaifenesin and dextromethorphan either used alone or combined with other active ingredients showed statistically significant improvements compared with placebo control in sputum looseness/adhesiveness and reductions in cough frequency/severity, respectively. A small number of studies did not show significant improvements with study drug compared with placebo control. Conflicting data may originate from differences in study design, patient enrollment, and a relatively high placebo control effect across studies.

Conclusion: The data reviewed in this article support the importance of guaifenesin and dextromethorphan in the armamentarium of effective nonprescription treatment options for cough and mucus-related cold symptoms.

目的:几十年来,愈创甘油醚和右美沙芬一直是治疗咳嗽和感冒症状的两种最完善和常用的非处方药。单一来源总结了支持使用愈创甘油醚和右美沙芬作为咳嗽和感冒的自我护理治疗选择的临床数据,可以帮助医疗保健专业人员(HCPs)向患者提出明智的建议。这篇叙述性综述的目的是通过检查含有愈创甘油醚和右美沙芬成分的产品的有效性和安全性的已发表数据,讨论愈创甘油醚和右美沙芬在治疗成人咳嗽和黏液相关感冒症状方面的益处。方法:在PubMed、Embase和MEDLINE上进行文献检索,以确定比较愈创尼松或右美沙芬治疗与安慰剂对照治疗成人咳嗽和感冒(粘液)症状的随机对照研究。在文献检索最初确定的36篇愈创甘油醚和53篇右美沙芬临床研究中,13篇愈创甘油醚和19篇右美沙芬出版物符合预定的纳入标准。在论文撰写过程中,通过审查纳入文章的引用,确定了其他研究,共有17篇愈创甘油醚和21篇右美沙芬出版物。结果:研究数据显示,与安慰剂对照相比,愈创甘油醚和右美沙芬单独使用或与其他活性成分联合使用在痰液疏松/粘连性和咳嗽频率/严重程度降低方面分别有统计学显著改善。与安慰剂对照相比,少数研究没有显示研究药物有显著改善。相互矛盾的数据可能源于研究设计、患者入组的差异,以及研究中相对较高的安慰剂对照效应。结论:本文回顾的数据支持愈创甘油醚和右美沙芬在咳嗽和黏液相关感冒症状的有效非处方治疗方案中的重要性。
{"title":"Guaifenesin and dextromethorphan for management of cough and mucus-related cold symptoms in adults: a narrative literature review.","authors":"M Thomas Bateman, Stephen Brunton, Wendy L Wright","doi":"10.1080/00325481.2025.2603034","DOIUrl":"10.1080/00325481.2025.2603034","url":null,"abstract":"<p><strong>Objectives: </strong>For many decades, guaifenesin and dextromethorphan have been two of the most well-established and commonly used nonprescription medications to manage cough and cold symptoms. A single source that summarizes the clinical data supporting the use of guaifenesin and dextromethorphan as self-care treatment options in cough and cold could assist healthcare professionals (HCPs) in making informed recommendations to patients. The objective of this narrative review is to discuss the benefits of guaifenesin and dextromethorphan for the management of cough and mucus-related cold symptoms in adults by examining published data on the effectiveness and safety of the products containing these ingredients.</p><p><strong>Methods: </strong>Literature searches were performed on PubMed, Embase, and MEDLINE to identify randomized, controlled studies comparing guaifenesin or dextromethorphan treatment with placebo control in adults with cough and cold (mucus) symptoms. Of 36 guaifenesin and 53 dextromethorphan clinical studies initially identified by the literature search, 13 guaifenesin and 19 dextromethorphan publications met the predefined inclusion criteria. Additional studies were identified during manuscript development by reviewing the citations of included articles, for a total of 17 guaifenesin and 21 dextromethorphan publications.</p><p><strong>Results: </strong>Data from studies of guaifenesin and dextromethorphan either used alone or combined with other active ingredients showed statistically significant improvements compared with placebo control in sputum looseness/adhesiveness and reductions in cough frequency/severity, respectively. A small number of studies did not show significant improvements with study drug compared with placebo control. Conflicting data may originate from differences in study design, patient enrollment, and a relatively high placebo control effect across studies.</p><p><strong>Conclusion: </strong>The data reviewed in this article support the importance of guaifenesin and dextromethorphan in the armamentarium of effective nonprescription treatment options for cough and mucus-related cold symptoms.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"741-755"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consistency of objective and subjective evidence for the efficacy of lemborexant. 香叶剂疗效的客观与主观证据的一致性。
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2026-01-08 DOI: 10.1080/00325481.2025.2609392
Charles M Morin, Alex Desautels, Dinesh Kumar, Kate Pinner, Barbara Ramos, Margaret Moline

Objectives: To review the efficacy of lemborexant (LEM), a dual orexin-receptor antagonist approved in multiple countries for treatment of insomnia in adults, by assessing the consistency of the available LEM objective and subjective evidence.

Methods: Data from 2 pivotal phase 3, randomized, double-blind, parallel-group, placebo (PBO)-controlled studies are reviewed. Study 304 (1-month) and Study 303 (12-months; only first 6 months included here) evaluated the efficacy/safety of LEM 5 mg (LEM5) and LEM 10 mg (LEM10) in adults with insomnia disorder. Objective sleep onset (latency to persistent sleep [LPS]) and sleep maintenance (wake after sleep onset [WASO] and total sleep time [TST]) were assessed with polysomnography in Study 304. Subjective sleep onset latency (sSOL) and sleep maintenance (sWASO and sTST) were assessed with sleep diaries in both studies. Other patient-reported efficacy measures included Insomnia Severity Index-total score (ISI-TS), ISI-daytime functioning (ISI-DF), Fatigue Severity Scale (FSS), and Patient Global Impression-Insomnia (PGI-I).

Results: Compared with PBO, significantly larger decreases (improvements) from baseline in LPS, sSOL, WASO, and sWASO and significantly larger increases (improvements) from baseline in TST and sTST were observed within the first week of LEM treatment (as early as within the first 1-2 nights) and were sustained throughout the treatment period (1-6 months) (all p < 0.05, except for sWASO at Month 1). These improvements aligned with significantly larger decreases (improvements) from baseline in ISI-TS, ISI-DF, and PGI-I (all p < 0.05). Significantly larger decreases (improvement) from baseline in FSS scores were observed at 3 and 6 months (both p < 0.05).

Conclusion: LEM showed concordance in its ability to improve objective and subjective measures of nighttime sleep, as well as daytime functioning and patient perception of nighttime sleep. These findings demonstrate that LEM is effective both objectively and from the patient's perspective, supporting LEM as a valuable treatment option for adults with insomnia.

目的:通过评估现有LEM客观和主观证据的一致性,回顾lemborexant (LEM)的疗效,LEM是一种双重食欲素受体拮抗剂,已在多个国家批准用于治疗成人失眠。方法:回顾了2个关键的3期、随机、双盲、平行组、安慰剂(PBO)对照研究的数据。研究304(1个月)和研究303(12个月,仅包括前6个月)评估了莱姆5mg (LEM5)和莱姆10mg (LEM10)对成人失眠障碍的疗效/安全性。目的:研究304采用多导睡眠图评估睡眠开始(持续睡眠潜伏期[LPS])和睡眠维持(睡眠后醒来[WASO]和总睡眠时间[TST])。主观睡眠发作潜伏期(sSOL)和睡眠维持时间(sWASO和sTST)均采用睡眠日记进行评估。其他患者报告的疗效测量包括失眠严重程度指数-总分(ISI-TS), isi -日间功能(ISI-DF),疲劳严重程度量表(FSS)和患者整体印象-失眠(gi - i)。结果:与PBO相比,LPS、sSOL、WASO和sWASO较基线显著下降(改善),TST和sTST较基线显著增加(改善)在LEM治疗的第一周内(早在前1-2晚),并持续整个治疗期间(1-6个月)(均p p p p)。LEM在改善夜间睡眠的客观和主观测量,以及白天功能和患者夜间睡眠感知方面表现出一致性。这些研究结果表明,无论从客观上还是从患者的角度来看,LEM都是有效的,支持LEM作为成年人失眠的有价值的治疗选择。
{"title":"Consistency of objective and subjective evidence for the efficacy of lemborexant.","authors":"Charles M Morin, Alex Desautels, Dinesh Kumar, Kate Pinner, Barbara Ramos, Margaret Moline","doi":"10.1080/00325481.2025.2609392","DOIUrl":"10.1080/00325481.2025.2609392","url":null,"abstract":"<p><strong>Objectives: </strong>To review the efficacy of lemborexant (LEM), a dual orexin-receptor antagonist approved in multiple countries for treatment of insomnia in adults, by assessing the consistency of the available LEM objective and subjective evidence.</p><p><strong>Methods: </strong>Data from 2 pivotal phase 3, randomized, double-blind, parallel-group, placebo (PBO)-controlled studies are reviewed. Study 304 (1-month) and Study 303 (12-months; only first 6 months included here) evaluated the efficacy/safety of LEM 5 mg (LEM5) and LEM 10 mg (LEM10) in adults with insomnia disorder. Objective sleep onset (latency to persistent sleep [LPS]) and sleep maintenance (wake after sleep onset [WASO] and total sleep time [TST]) were assessed with polysomnography in Study 304. Subjective sleep onset latency (sSOL) and sleep maintenance (sWASO and sTST) were assessed with sleep diaries in both studies. Other patient-reported efficacy measures included Insomnia Severity Index-total score (ISI-TS), ISI-daytime functioning (ISI-DF), Fatigue Severity Scale (FSS), and Patient Global Impression-Insomnia (PGI-I).</p><p><strong>Results: </strong>Compared with PBO, significantly larger decreases (improvements) from baseline in LPS, sSOL, WASO, and sWASO and significantly larger increases (improvements) from baseline in TST and sTST were observed within the first week of LEM treatment (as early as within the first 1-2 nights) and were sustained throughout the treatment period (1-6 months) (all <i>p</i> < 0.05, except for sWASO at Month 1). These improvements aligned with significantly larger decreases (improvements) from baseline in ISI-TS, ISI-DF, and PGI-I (all <i>p</i> < 0.05). Significantly larger decreases (improvement) from baseline in FSS scores were observed at 3 and 6 months (both <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>LEM showed concordance in its ability to improve objective and subjective measures of nighttime sleep, as well as daytime functioning and patient perception of nighttime sleep. These findings demonstrate that LEM is effective both objectively and from the patient's perspective, supporting LEM as a valuable treatment option for adults with insomnia.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"756-765"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional deficiencies as risk factors for incidence and treatment response of tinea capitis in children: a prospective clinical cohort study. 营养缺乏是儿童头癣发病率和治疗反应的危险因素:一项前瞻性临床队列研究。
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-12-30 DOI: 10.1080/00325481.2025.2609382
Khaled Seetan, Almu'atasim Khamees, Raghad Yousef Yassin, Saleh A Ba-Shammakh, Amir Majdi Moh'd

Objectives: Tinea capitis is one of the most common fungal infections in children around the world. However, the relationship between nutrition and the risk of infection, as well as treatment outcomes, has not been thoroughly studied. This study aimed to explore the relationship between certain micronutrient deficiencies and the occurrence, severity, and treatment response of tinea capitis in children.

Methods: This prospective cohort study included 280 children aged 2-12 years, with 140 confirmed cases of tinea capitis and 140 matched controls from three clinical locations. Detailed nutritional assessments included growth measurements and lab tests for zinc, iron, vitamin D, and protein-energy levels. The cases received standard antifungal treatment and were monitored for 6 months to evaluate treatment results. We employed multivariate analyses to identify relationships between nutritional factors and the occurrence, severity, and treatment outcomes of the disease.

Results: Even after controlling for other variables, zinc deficiency (OR = 2.87, 95% CI [1.71, 4.84], p < 0.001) and vitamin D deficiency (OR = 2.11, 95% CI [1.25, 3.58], p = 0.005) were found to increase the risk of tinea capitis independently. The symptoms and outcomes of treatment were worse in children with multiple nutritional deficiencies. At 8 weeks, children with nutritional deficiencies had a significantly lower rate of clinical cure (44.2%) than those without (71.4%, p < 0.001). The relationship between treatment response and socioeconomic status was significantly influenced by nutritional status.

Conclusions: Low levels of certain micronutrients, especially zinc and vitamin D, are key risk factors for children developing tinea capitis and not responding well to treatment. These findings suggest the potential benefits of integrated nutritional assessment and focused supplementation strategies, which should be evaluated in future interventional trials for pediatric tinea capitis, especially in resource-limited settings.

目的:头癣是世界上儿童最常见的真菌感染之一。然而,营养与感染风险以及治疗结果之间的关系尚未得到彻底研究。本研究旨在探讨某些微量营养素缺乏与儿童头癣的发生、严重程度和治疗反应之间的关系。方法:这项前瞻性队列研究包括280名2-12岁的儿童,140例确诊的头癣病例和140例匹配的对照组,来自三个临床地点。详细的营养评估包括生长测量和锌、铁、维生素D和蛋白质能量水平的实验室测试。病例接受标准抗真菌治疗,并监测6个月以评估治疗效果。我们采用多变量分析来确定营养因素与疾病的发生、严重程度和治疗结果之间的关系。结果:即使在控制了其他变量后,锌缺乏(OR = 2.87, 95% CI [1.71, 4.84], p = 0.005)仍可独立增加头癣的发生风险。多重营养缺乏症患儿的症状和治疗效果更差。8周时,营养缺乏儿童的临床治愈率(44.2%)明显低于无营养缺乏儿童的临床治愈率(71.4%)。结论:某些微量营养素水平低,特别是锌和维生素D水平低,是儿童发生头癣且治疗效果不佳的关键危险因素。这些发现表明,综合营养评估和重点补充策略的潜在益处,应在未来对儿童头癣的介入试验中进行评估,特别是在资源有限的情况下。
{"title":"Nutritional deficiencies as risk factors for incidence and treatment response of tinea capitis in children: a prospective clinical cohort study.","authors":"Khaled Seetan, Almu'atasim Khamees, Raghad Yousef Yassin, Saleh A Ba-Shammakh, Amir Majdi Moh'd","doi":"10.1080/00325481.2025.2609382","DOIUrl":"10.1080/00325481.2025.2609382","url":null,"abstract":"<p><strong>Objectives: </strong>Tinea capitis is one of the most common fungal infections in children around the world. However, the relationship between nutrition and the risk of infection, as well as treatment outcomes, has not been thoroughly studied. This study aimed to explore the relationship between certain micronutrient deficiencies and the occurrence, severity, and treatment response of tinea capitis in children.</p><p><strong>Methods: </strong>This prospective cohort study included 280 children aged 2-12 years, with 140 confirmed cases of tinea capitis and 140 matched controls from three clinical locations. Detailed nutritional assessments included growth measurements and lab tests for zinc, iron, vitamin D, and protein-energy levels. The cases received standard antifungal treatment and were monitored for 6 months to evaluate treatment results. We employed multivariate analyses to identify relationships between nutritional factors and the occurrence, severity, and treatment outcomes of the disease.</p><p><strong>Results: </strong>Even after controlling for other variables, zinc deficiency (OR = 2.87, 95% CI [1.71, 4.84], <i>p</i> < 0.001) and vitamin D deficiency (OR = 2.11, 95% CI [1.25, 3.58], <i>p</i> = 0.005) were found to increase the risk of tinea capitis independently. The symptoms and outcomes of treatment were worse in children with multiple nutritional deficiencies. At 8 weeks, children with nutritional deficiencies had a significantly lower rate of clinical cure (44.2%) than those without (71.4%, <i>p</i> < 0.001). The relationship between treatment response and socioeconomic status was significantly influenced by nutritional status.</p><p><strong>Conclusions: </strong>Low levels of certain micronutrients, especially zinc and vitamin D, are key risk factors for children developing tinea capitis and not responding well to treatment. These findings suggest the potential benefits of integrated nutritional assessment and focused supplementation strategies, which should be evaluated in future interventional trials for pediatric tinea capitis, especially in resource-limited settings.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"887-896"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145859857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estrogen-sensitive menstrual cycle-dependent premature ventricular contractions successfully treated with combined contraceptive therapy: a case report. 雌激素敏感月经周期依赖性室性早衰成功联合避孕治疗:一例报告。
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-10-27 DOI: 10.1080/00325481.2025.2580735
Xi Xia, Hongli Meng, Jianbo Li, Erying Shu, Miao Chen

Introduction: The effects of estrogen on arrhythmias are controversial. While animal studies suggest complex effects, the hypothesis that higher estrogen levels increase women's arrhythmia susceptibility has not yet been fully validated in human studies.

Case report: This case report describes a 30-year-old female patient who frequently experienced palpitations and was initially diagnosed with idiopathic ventricular arrhythmia. However, her symptoms were strongly correlated with her menstrual cycle. She experienced premature ventricular contractions (PVCs) 6 days before menstruation and 5 days before ovulation, which coincided with elevated estrogen levels. After other potential causes were ruled out, a diagnosis of hormone-induced PVCs was established. The patient was treated with a combination of estrogen and progestogen that not only alleviated her palpitations but also relieved her dysmenorrhea and menstrual irregularities. During a 5-month follow-up period, the patient reported no further palpitations.

Conclusion: This case provides clinical support of the hypothesis that elevated estrogen levels can increase vulnerability to ventricular arrhythmias in women. The influence of estrogen on arrhythmias may occur via a biphasic effect that potentially provides antiarrhythmic benefits during phases of low estrogen and increases the risk of arrhythmia during peak estrogen phases. Clinicians should consider hormone-related arrhythmias when young female patients present with palpitations that follow a cyclical pattern that is clearly linked to the menstrual cycle. Such cases warrant thorough history-taking and assessments of sex hormone levels. Hormonal regulation therapy could be an effective treatment strategy; however, its effectiveness and safety require careful evaluation.

引言:雌激素对心律失常的影响是有争议的。虽然动物研究显示了复杂的影响,但雌激素水平升高会增加女性心律失常易感性的假设尚未在人体研究中得到充分证实。病例报告:本病例报告描述了一位30岁的女性患者,她经常经历心悸,最初被诊断为特发性室性心律失常。然而,她的症状与她的月经周期密切相关。患者在月经前6天和排卵前5天出现室性早搏,与雌激素水平升高同时发生。在排除了其他可能的原因后,确定了激素诱发的室性早搏的诊断。患者采用雌激素和孕激素联合治疗,不仅缓解了心悸,而且缓解了痛经和月经不规律。在5个月的随访期间,患者无进一步心悸。结论:本病例为雌激素水平升高可增加女性室性心律失常易感性的假说提供了临床支持。雌激素对心律失常的影响可能是通过双相效应发生的,双相效应可能在低雌激素期提供抗心律失常的益处,并增加雌激素高峰期心律失常的风险。当年轻女性患者心悸遵循明显与月经周期相关的周期性模式时,临床医生应考虑激素相关的心律失常。这样的病例需要彻底记录病史并评估性激素水平。激素调节疗法可能是一种有效的治疗策略;然而,其有效性和安全性需要仔细评估。
{"title":"Estrogen-sensitive menstrual cycle-dependent premature ventricular contractions successfully treated with combined contraceptive therapy: a case report.","authors":"Xi Xia, Hongli Meng, Jianbo Li, Erying Shu, Miao Chen","doi":"10.1080/00325481.2025.2580735","DOIUrl":"10.1080/00325481.2025.2580735","url":null,"abstract":"<p><strong>Introduction: </strong>The effects of estrogen on arrhythmias are controversial. While animal studies suggest complex effects, the hypothesis that higher estrogen levels increase women's arrhythmia susceptibility has not yet been fully validated in human studies.</p><p><strong>Case report: </strong>This case report describes a 30-year-old female patient who frequently experienced palpitations and was initially diagnosed with idiopathic ventricular arrhythmia. However, her symptoms were strongly correlated with her menstrual cycle. She experienced premature ventricular contractions (PVCs) 6 days before menstruation and 5 days before ovulation, which coincided with elevated estrogen levels. After other potential causes were ruled out, a diagnosis of hormone-induced PVCs was established. The patient was treated with a combination of estrogen and progestogen that not only alleviated her palpitations but also relieved her dysmenorrhea and menstrual irregularities. During a 5-month follow-up period, the patient reported no further palpitations.</p><p><strong>Conclusion: </strong>This case provides clinical support of the hypothesis that elevated estrogen levels can increase vulnerability to ventricular arrhythmias in women. The influence of estrogen on arrhythmias may occur via a biphasic effect that potentially provides antiarrhythmic benefits during phases of low estrogen and increases the risk of arrhythmia during peak estrogen phases. Clinicians should consider hormone-related arrhythmias when young female patients present with palpitations that follow a cyclical pattern that is clearly linked to the menstrual cycle. Such cases warrant thorough history-taking and assessments of sex hormone levels. Hormonal regulation therapy could be an effective treatment strategy; however, its effectiveness and safety require careful evaluation.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"719-723"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperkalemia in the neonatal intensive care unit: actual or pseudohyperkalemia? 新生儿重症监护室的高钾血症:实际高钾血症还是假性高钾血症?
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-12-09 DOI: 10.1080/00325481.2025.2601348
Duygu Aydın, Ayla Günlemez

Introduction: Hyperkalemia is a critical electrolyte imbalance in neonatal intensive care unit (NICU), linked to increased mortality. This study aimed to determine the prevalence, etiological factors, and clinical outcomes of hyperkalemia in neonates admitted to the NICU over a 10-year period, with a specific focus on differentiating actual hyperkalemia from pseudohyperkalemia according to gestational age - based thresholds.

Materials and methods: Data from NICU admissions over 10 years were analyzed. Hyperkalemia was defined as potassium levels ≥6 mmol/L in term neonates and >6.5 mmol/L in preterm. Cases of pseudohyperkalemia, primary etiology, and mortality were assessed.

Results: Among 5997 admissions, hyperkalemia was observed in 4.9% of cases, while true hyperkalemia was confirmed in 1.6%. Pseudohyperkalemia was the most common type. Actual hyperkalemia was more frequent in term neonates (p = 0.016). Acute kidney injury (AKI) was identified in 43.6% of cases. In term neonates, the most common causes were asphyxia, AKI, and congenital adrenal hyperplasia, whereas in preterms, they were AKI, hypoxia, and hemorrhage. A negative correlation was found between Apgar scores and potassium levels (p < 0.001). Mortality rates were 7.2% in neonates without actual hyperkalemia and 37.2% in those with it.

Conclusion: Hyperkalemia is a common and serious condition in NICUs, requiring prompt differentiation of pseudohyperkalemia from actual hyperkalemia. Given its high mortality risk, rapid etiology-specific treatment and potassium-lowering therapies are essential for managing actual hyperkalemia.

高钾血症是新生儿重症监护病房(NICU)的一种关键电解质失衡,与死亡率增加有关。本研究旨在确定10年间入住NICU的新生儿高钾血症的患病率、病因和临床结果,并根据胎龄阈值特别关注区分实际高钾血症和假性高钾血症。材料和方法:对近10年新生儿重症监护病房入院数据进行分析。高钾血症定义为足月新生儿钾水平≥6 mmol/L,早产儿钾水平≥6.5 mmol/L。假性高钾血症病例,主要病因和死亡率进行评估。结果:入院的5997例患者中,高钾血症发生率为4.9%,真性高钾血症发生率为1.6%。假性高钾血症是最常见的类型。实际高钾血症在足月新生儿中更为常见(p = 0.016)。43.6%的病例为急性肾损伤(AKI)。在足月新生儿中,最常见的原因是窒息、AKI和先天性肾上腺增生,而在早产儿中,最常见的原因是AKI、缺氧和出血。结论:高钾血症在新生儿重症监护病房中是一种常见且严重的疾病,需要及时区分假高钾血症和实际高钾血症。鉴于其高死亡率风险,快速的病因特异性治疗和降钾疗法对于管理实际高钾血症至关重要。
{"title":"Hyperkalemia in the neonatal intensive care unit: actual or pseudohyperkalemia?","authors":"Duygu Aydın, Ayla Günlemez","doi":"10.1080/00325481.2025.2601348","DOIUrl":"10.1080/00325481.2025.2601348","url":null,"abstract":"<p><strong>Introduction: </strong>Hyperkalemia is a critical electrolyte imbalance in neonatal intensive care unit (NICU), linked to increased mortality. This study aimed to determine the prevalence, etiological factors, and clinical outcomes of hyperkalemia in neonates admitted to the NICU over a 10-year period, with a specific focus on differentiating actual hyperkalemia from pseudohyperkalemia according to gestational age - based thresholds.</p><p><strong>Materials and methods: </strong>Data from NICU admissions over 10 years were analyzed. Hyperkalemia was defined as potassium levels ≥6 mmol/L in term neonates and >6.5 mmol/L in preterm. Cases of pseudohyperkalemia, primary etiology, and mortality were assessed.</p><p><strong>Results: </strong>Among 5997 admissions, hyperkalemia was observed in 4.9% of cases, while true hyperkalemia was confirmed in 1.6%. Pseudohyperkalemia was the most common type. Actual hyperkalemia was more frequent in term neonates (<i>p</i> = 0.016). Acute kidney injury (AKI) was identified in 43.6% of cases. In term neonates, the most common causes were asphyxia, AKI, and congenital adrenal hyperplasia, whereas in preterms, they were AKI, hypoxia, and hemorrhage. A negative correlation was found between Apgar scores and potassium levels (<i>p</i> < 0.001). Mortality rates were 7.2% in neonates without actual hyperkalemia and 37.2% in those with it.</p><p><strong>Conclusion: </strong>Hyperkalemia is a common and serious condition in NICUs, requiring prompt differentiation of pseudohyperkalemia from actual hyperkalemia. Given its high mortality risk, rapid etiology-specific treatment and potassium-lowering therapies are essential for managing actual hyperkalemia.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"814-819"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing mortality prediction by incorporating depression into life's essential 8 in diabetic and prediabetic populations: evidence from NHANES 2009-2016. 通过将抑郁症纳入糖尿病和糖尿病前期人群的生活必需品,提高死亡率预测:来自NHANES 2009-2016的证据。
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-12-28 DOI: 10.1080/00325481.2025.2609372
Wenrui Shi, Yangbin Shi, Jieun Park, Shaohui Wu

Background: Life's Crucial 9 (LC9) was recently proposed by adding depression to Life's Essential 8 (LE8) to better predict future health risks. However, its superiority over LE8 in predicting outcomes in individuals with prediabetes or diabetes remains unclear.

Methods: We analyzed data from 7044 individuals with diabetes or prediabetes from the National Health and Nutrition Examination Survey (NHANES). LC9 was calculated as the mean of the LE8 score and a depression score, representing psychological health. We used Cox regression to assess the association of these scores with all-cause and cardiovascular mortality. Receiver operating characteristic curves and reclassification analyses were employed to compare predictive performance.

Results: During a median follow-up of 6.58 years (IQR: 4.67-8.75), 782 participants (11.10%) died, with 243 (3.45%) from cardiovascular causes. Each 10-point increase in LE8 score was associated with a hazard ratio (HR) of 0.807 (95% CI: 0.733-0.888) for all-cause mortality, while LC9 showed a stronger association with HR 0.750 (95% CI: 0.673-0.835). LC9 significantly improved the prediction of all-cause mortality (AUC 0.574 vs. 0.589, p = 0.021), supported by reclassification indices (p < 0.001). However, for cardiovascular mortality, both scores showed similar HRs, and no improvement was observed with LC9.

Conclusions: Incorporating depression into LE8 could improve the prediction of all-cause mortality in diabetic and prediabetic populations. Given its practicality and low cost, routine depression screening may offer a feasible strategy to enhance risk stratification in primary care settings.

背景:Life's Crucial 9 (LC9)最近被提出,将抑郁添加到Life's Essential 8 (LE8)中,以更好地预测未来的健康风险。然而,在预测糖尿病前期或糖尿病患者预后方面,其优于LE8的优势尚不清楚。方法:我们分析了来自国家健康与营养调查(NHANES)的7044名糖尿病或前驱糖尿病患者的数据。LC9计算为LE8评分和抑郁评分的平均值,代表心理健康。我们使用Cox回归来评估这些评分与全因死亡率和心血管死亡率的关系。采用受试者工作特征曲线和再分类分析比较预测效果。结果:在中位随访6.58年(IQR: 4.67-8.75)期间,782名参与者(11.10%)死亡,其中243名(3.45%)死于心血管原因。LE8评分每增加10分,全因死亡率的风险比(HR)为0.807 (95% CI: 0.733-0.888), LC9评分与HR 0.750 (95% CI: 0.673-0.835)的相关性更强。LC9显著改善了全因死亡率的预测(AUC 0.574比0.589,p = 0.021),这得到了重分类指数的支持(p结论:将抑郁纳入LE8可改善糖尿病和糖尿病前期人群全因死亡率的预测。鉴于其实用性和低成本,常规抑郁症筛查可能为加强初级保健机构的风险分层提供可行的策略。
{"title":"Enhancing mortality prediction by incorporating depression into life's essential 8 in diabetic and prediabetic populations: evidence from NHANES 2009-2016.","authors":"Wenrui Shi, Yangbin Shi, Jieun Park, Shaohui Wu","doi":"10.1080/00325481.2025.2609372","DOIUrl":"10.1080/00325481.2025.2609372","url":null,"abstract":"<p><strong>Background: </strong>Life's Crucial 9 (LC9) was recently proposed by adding depression to Life's Essential 8 (LE8) to better predict future health risks. However, its superiority over LE8 in predicting outcomes in individuals with prediabetes or diabetes remains unclear.</p><p><strong>Methods: </strong>We analyzed data from 7044 individuals with diabetes or prediabetes from the National Health and Nutrition Examination Survey (NHANES). LC9 was calculated as the mean of the LE8 score and a depression score, representing psychological health. We used Cox regression to assess the association of these scores with all-cause and cardiovascular mortality. Receiver operating characteristic curves and reclassification analyses were employed to compare predictive performance.</p><p><strong>Results: </strong>During a median follow-up of 6.58 years (IQR: 4.67-8.75), 782 participants (11.10%) died, with 243 (3.45%) from cardiovascular causes. Each 10-point increase in LE8 score was associated with a hazard ratio (HR) of 0.807 (95% CI: 0.733-0.888) for all-cause mortality, while LC9 showed a stronger association with HR 0.750 (95% CI: 0.673-0.835). LC9 significantly improved the prediction of all-cause mortality (AUC 0.574 vs. 0.589, <i>p</i> = 0.021), supported by reclassification indices (<i>p</i> < 0.001). However, for cardiovascular mortality, both scores showed similar HRs, and no improvement was observed with LC9.</p><p><strong>Conclusions: </strong>Incorporating depression into LE8 could improve the prediction of all-cause mortality in diabetic and prediabetic populations. Given its practicality and low cost, routine depression screening may offer a feasible strategy to enhance risk stratification in primary care settings.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"876-886"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145852099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality risk factors among patients with necrotizing fasciitis: a systematic review and meta-analysis of cohort studies. 坏死性筋膜炎患者的死亡危险因素:队列研究的系统回顾和荟萃分析。
IF 2.8 Pub Date : 2025-11-01 Epub Date: 2025-12-17 DOI: 10.1080/00325481.2025.2604332
Weizheng Huang, Jiaqi Wei, Yujiao Wu, Chengzi Huang, Yaling Li, Jun Li

Objective: To identify key risk factors associated with mortality in necrotizing fasciitis (NF) and provide clinicians with evidence-based guidance for risk stratification and management.

Methods: A systematic review and meta-analysis was conducted. PubMed, Embase, Web of Science, Cochrane Library, and ProQuest were searched from inception to 19 May 2023, with an update on 31 May 2025. Cohort studies reporting adjusted risk estimates for NF-related mortality were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.

Results: Of 30,563 identified articles, 14 studies involving 26,242 patients were included. The strongest predictors of NF mortality were advanced age (odds ratio [OR] 1.160, 95% CI 1.100-1.223), cardiopathy (OR 2.210, 95% CI 1.274-3.833), elevated creatinine (OR 2.200, 95% CI 1.127-4.294), and Clostridium infection (OR 6.422, 95% CI 2.171-19.003). Race appeared protective, particularly among Black patients (OR 0.780, 95% CI 0.645-0.943). No significant associations were found for gender, pneumopathy, hepatopathy, nephropathy, diabetes, malignancy, or several laboratory and microbial factors.

Conclusions: Advanced age, cardiopathy, elevated creatinine, and Clostridium infection are significant mortality risk factors in NF. Race may have a protective effect. Further research is warranted to clarify the roles of other clinical and laboratory variables.

目的:探讨与坏死性筋膜炎(NF)死亡率相关的关键危险因素,为临床医生进行风险分层和管理提供循证指导。方法:进行系统综述和荟萃分析。PubMed, Embase, Web of Science, Cochrane Library和ProQuest从成立到2023年5月19日进行了检索,并于2025年5月31日进行了更新。纳入了报告nf相关死亡率调整风险估计值的队列研究。计算合并优势比(ORs)和95%置信区间(ci)。结果:在30,563篇确定的文章中,纳入了14项研究,涉及26,242例患者。NF死亡率的最强预测因子是高龄(比值比[OR] 1.160, 95% CI 1.100-1.223)、心脏病(OR 2.210, 95% CI 1.274-3.833)、肌酐升高(OR 2.200, 95% CI 1.127-4.294)和梭状芽胞杆菌感染(OR 6.422, 95% CI 2.171-19.003)。种族表现出保护作用,尤其是黑人患者(OR 0.780, 95% CI 0.645-0.943)。性别、肺病、肝病、肾病、糖尿病、恶性肿瘤或一些实验室和微生物因素未发现显著相关性。结论:高龄、心脏病、肌酐升高和梭状芽胞杆菌感染是NF的重要死亡危险因素。种族可能有保护作用。进一步的研究是必要的,以澄清其他临床和实验室变量的作用。
{"title":"Mortality risk factors among patients with necrotizing fasciitis: a systematic review and meta-analysis of cohort studies.","authors":"Weizheng Huang, Jiaqi Wei, Yujiao Wu, Chengzi Huang, Yaling Li, Jun Li","doi":"10.1080/00325481.2025.2604332","DOIUrl":"10.1080/00325481.2025.2604332","url":null,"abstract":"<p><strong>Objective: </strong>To identify key risk factors associated with mortality in necrotizing fasciitis (NF) and provide clinicians with evidence-based guidance for risk stratification and management.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted. PubMed, Embase, Web of Science, Cochrane Library, and ProQuest were searched from inception to 19 May 2023, with an update on 31 May 2025. Cohort studies reporting adjusted risk estimates for NF-related mortality were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Of 30,563 identified articles, 14 studies involving 26,242 patients were included. The strongest predictors of NF mortality were advanced age (odds ratio [OR] 1.160, 95% CI 1.100-1.223), cardiopathy (OR 2.210, 95% CI 1.274-3.833), elevated creatinine (OR 2.200, 95% CI 1.127-4.294), and <i>Clostridium</i> infection (OR 6.422, 95% CI 2.171-19.003). Race appeared protective, particularly among Black patients (OR 0.780, 95% CI 0.645-0.943). No significant associations were found for gender, pneumopathy, hepatopathy, nephropathy, diabetes, malignancy, or several laboratory and microbial factors.</p><p><strong>Conclusions: </strong>Advanced age, cardiopathy, elevated creatinine, and <i>Clostridium</i> infection are significant mortality risk factors in NF. Race may have a protective effect. Further research is warranted to clarify the roles of other clinical and laboratory variables.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"850-856"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Postgraduate medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1